NYSE:IKT

Inhibikase Therapeutics Competitors

$5.31
-0.12 (-2.21 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.21
Now: $5.31
$5.59
50-Day Range
$5.20
MA: $6.06
$7.31
52-Week Range
$5.12
Now: $5.31
$11.80
Volume11,962 shs
Average Volume99,742 shs
Market Capitalization$53.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Inhibikase Therapeutics (NYSE:IKT) Vs. IPA, LBPH, ANVS, GANX, VINC, and EVAX

Should you be buying IKT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Inhibikase Therapeutics, including ImmunoPrecise Antibodies (IPA), Longboard Pharmaceuticals (LBPH), Annovis Bio (ANVS), Gain Therapeutics (GANX), Vincerx Pharma (VINC), and Evaxion Biotech A/S (EVAX).

ImmunoPrecise Antibodies (NASDAQ:IPA) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Earnings and Valuation

This table compares ImmunoPrecise Antibodies and Inhibikase Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares ImmunoPrecise Antibodies and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoPrecise AntibodiesN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for ImmunoPrecise Antibodies and Inhibikase Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoPrecise Antibodies01002.00
Inhibikase Therapeutics0000N/A

Longboard Pharmaceuticals (NASDAQ:LBPH) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Longboard Pharmaceuticals and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longboard PharmaceuticalsN/AN/AN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Longboard Pharmaceuticals and Inhibikase Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longboard Pharmaceuticals00503.00
Inhibikase Therapeutics0000N/A

Longboard Pharmaceuticals presently has a consensus target price of $32.75, suggesting a potential upside of 169.55%. Given Longboard Pharmaceuticals' higher possible upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Inhibikase Therapeutics.

Profitability

This table compares Longboard Pharmaceuticals and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Longboard PharmaceuticalsN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/A

Summary

Longboard Pharmaceuticals beats Inhibikase Therapeutics on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Annovis Bio and Inhibikase Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Annovis Bio0000N/A
Inhibikase Therapeutics0000N/A

Profitability

This table compares Annovis Bio and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Annovis BioN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Annovis Bio and Inhibikase Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/AN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/AN/AN/A

Inhibikase Therapeutics (NYSE:IKT) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Inhibikase Therapeutics and Gain Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibikase Therapeutics0000N/A
Gain Therapeutics00203.00

Gain Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 113.93%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Inhibikase Therapeutics.

Profitability

This table compares Inhibikase Therapeutics and Gain Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inhibikase TherapeuticsN/AN/AN/A
Gain TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Inhibikase Therapeutics and Gain Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase TherapeuticsN/AN/AN/AN/AN/A
Gain TherapeuticsN/AN/AN/AN/AN/A

Summary

Gain Therapeutics beats Inhibikase Therapeutics on 2 of the 2 factors compared between the two stocks.

Inhibikase Therapeutics (NYSE:IKT) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Valuation & Earnings

This table compares Inhibikase Therapeutics and Vincerx Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase TherapeuticsN/AN/AN/AN/AN/A
Vincerx PharmaN/AN/AN/AN/AN/A

Profitability

This table compares Inhibikase Therapeutics and Vincerx Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inhibikase TherapeuticsN/AN/AN/A
Vincerx PharmaN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Inhibikase Therapeutics and Vincerx Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inhibikase Therapeutics0000N/A
Vincerx Pharma00103.00

Given Vincerx Pharma's higher possible upside, analysts plainly believe Vincerx Pharma is more favorable than Inhibikase Therapeutics.

Summary

Vincerx Pharma beats Inhibikase Therapeutics on 2 of the 2 factors compared between the two stocks.

Evaxion Biotech A/S (NASDAQ:EVAX) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Inhibikase Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/AN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Evaxion Biotech A/S and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evaxion Biotech A/SN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Evaxion Biotech A/S and Inhibikase Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evaxion Biotech A/S00203.00
Inhibikase Therapeutics0000N/A

Evaxion Biotech A/S currently has a consensus target price of $18.00, suggesting a potential upside of 145.57%. Given Evaxion Biotech A/S's higher probable upside, equities analysts clearly believe Evaxion Biotech A/S is more favorable than Inhibikase Therapeutics.

Summary

Evaxion Biotech A/S beats Inhibikase Therapeutics on 2 of the 2 factors compared between the two stocks.


Inhibikase Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.94-7.3%$209.16 millionN/A0.00Increase in Short Interest
LBPH
Longboard Pharmaceuticals
1.9$12.15-2.4%$205.54 millionN/A0.00Analyst Report
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$22.90-5.4%$159.09 millionN/A0.00
GANX
Gain Therapeutics
1.7$14.02-5.8%$158.90 millionN/A0.00Analyst Report
VINC
Vincerx Pharma
1.0$19.05-0.6%$156.31 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$7.33-11.2%$140.73 millionN/A0.00News Coverage
LGVN
Longeveron
0.3$7.49-2.3%$140.12 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.92-4.3%$85.26 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$14.46-6.3%$56.51 millionN/A0.00Decrease in Short Interest
VIRI
Virios Therapeutics
1.3$5.90-0.8%$49.15 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.29-2.1%$38.75 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.87-5.1%$33.17 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3N/AN/A$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$35.01-12.4%$16.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.84-4.9%$15.69 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.20-12.8%$2.47 millionN/A0.00Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.73-5.5%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.81-2.8%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00Increase in Short Interest
RPHM
Reneo Pharmaceuticals
0.3$12.32-0.7%$0.00N/A0.00Insider Buying
News Coverage
SCPS
Scopus BioPharma
1.4$7.82-0.4%$0.00N/A0.00Increase in Short Interest
VECT
VectivBio
0.0$16.65-4.9%$0.00N/A0.00News Coverage
Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.